advent
product
biolog
lieu
harvest
anim
protein
ie
insulin
human
cadav
protein
ie
growth
hormon
revolution
treatment
diseas
fruit
biotechnolog
revolut
wide
acknowledg
realiz
differ
mean
product
chang
manner
control
potenti
impur
contamin
regard
new
versu
old
less
wide
appreci
chapter
overview
biolog
revolut
term
rigor
manufactur
requir
produc
mechan
action
caveat
endotoxin
control
continul
previou
chapter
establish
basic
background
knowledg
adapt
immun
principl
necessari
understand
mode
action
diseas
causat
biolog
therapeut
treatment
via
immun
modul
let
us
consid
differ
respect
distribut
metabol
serum
halflif
typic
dose
regimen
toxic
speci
reactiv
antigen
clearanc
mechan
drugdrug
interact
especi
smdbiolog
drug
interact
manufactur
therapeut
applic
biolog
present
complex
endeavor
microbiolog
control
personnel
need
primer
complex
subject
biolog
readili
avail
singl
sourc
biolog
mode
action
base
upon
immun
modul
manufactur
diverg
basic
histor
disciplin
becom
much
highli
special
form
somewhat
inher
tension
need
immunolog
background
understand
chang
precept
affect
microbiolog
contamin
control
mcc
yet
nonimmunologyexpert
specialist
expect
obtain
expert
understand
concept
explod
complex
last
ten
year
biolog
continu
larg
volum
parenter
lvp
small
molecul
drug
smd
mani
signific
differ
biolog
lvp
smd
lvp
among
oldest
inject
therapi
contain
simpl
ingredi
salt
sugar
electrolyt
etc
gener
activ
ingredi
wherea
typic
smd
contain
chemic
synthes
activ
pharmaceut
ingredi
api
modern
biolog
geneticallyengin
clone
human
gene
natur
sourc
produc
recombin
protein
sugar
nucleic
acid
complex
combin
also
may
whole
cell
tissu
blood
compon
antibodi
etc
differ
accru
term
molecul
mean
product
overview
biolog
larg
complex
molecul
especi
monoclon
shown
fig
thu
must
produc
live
express
system
bacteri
yeast
plant
mammalian
etc
complex
chemic
synthes
grown
seri
cell
cultur
tank
quot
focus
specif
manner
biolog
differ
smd
accord
ganellin
jefferi
robert
one
consid
size
biomolecular
drug
recogn
technolog
give
rise
biomolecular
drug
must
consider
differ
classic
smd
genentech
equat
differ
aspirin
atom
antibodi
atom
differ
weight
bicycl
lb
busi
jet
lb
accord
usp
biolog
larg
molecul
medicin
complex
natur
often
produc
live
express
system
preexist
small
molecul
counterpart
chemic
defin
molecul
often
produc
chemic
synthesi
pharmaceut
industri
shift
produc
predominantli
small
molecul
drug
manufactur
plethora
larg
molecul
drug
manufactur
adapt
exist
research
tool
product
process
analyt
method
also
develop
novel
technolog
approach
result
qualiti
standard
also
evolv
suit
new
paradigm
scientif
complex
present
revolutionari
biolog
therapeut
detail
overview
rel
size
variou
biolog
molecul
includ
mab
vaccin
viruslik
particl
outer
membran
vesicl
rel
variou
whole
cell
type
see
van
der
pol
stork
van
der
ley
biolog
older
class
mani
realiz
see
chap
began
develop
vaccin
earli
pasteurroux
develop
vaccin
rabi
jenner
smallpox
treatment
use
earli
like
use
even
earlier
chines
base
upon
paradigm
manufactur
manufactur
product
rather
upon
observ
milk
maid
routin
caught
cow
pox
seem
get
small
pox
thu
pu
sore
could
use
prevent
inocul
pasteur
began
understand
develop
appli
specif
scientif
principl
germ
theori
prior
develop
widelypublic
vaccin
rabi
pasteur
work
vaccin
chicken
cholera
anthrax
pasteur
stori
particularli
compel
save
young
french
boy
life
joseph
meister
upon
first
use
vaccin
human
year
subsequ
first
vaccin
surpris
number
vaccin
develop
mankind
worst
diseas
includ
diphtheria
plagu
tetanu
tuberculosi
yellow
fever
measl
mump
rubella
earli
effort
show
legitim
treatment
develop
har
power
mammalian
immun
system
via
use
anim
serum
antitoxin
vaccin
level
sophist
surpris
given
state
scientif
knowledg
time
kind
earli
prepar
biolog
deriv
live
cell
think
today
term
biolog
biolog
modern
sens
class
therapeut
produc
recombin
dna
technolog
gene
insert
cell
cultur
organ
typic
mammalian
microb
growth
express
system
plant
transgen
anim
molecul
thusli
produc
fall
sever
differ
class
see
sect
biolog
truli
result
biotechnolog
revolut
began
genentech
licens
recombin
human
insulin
rhi
eli
lilli
product
product
recombin
human
growth
hormon
rhgh
follow
dalton
amino
acid
rhi
closer
peptid
drug
rather
size
complex
modern
biolog
especi
compar
monoclon
antibodi
around
dalton
fig
hgh
also
rather
small
biolog
molecular
weight
dalton
amino
acid
window
power
biotechnolog
techniqu
fig
consid
advent
rhi
subsequ
chang
structur
insulin
molecul
use
meet
need
variou
dose
regimen
protein
sequenc
tweak
creat
fast
act
short
act
long
act
intermedi
act
regimen
drug
oppos
natur
intern
secret
absorpt
occur
constantli
insid
healthi
human
bodi
insulin
sever
challeng
includ
mode
administr
dosag
time
rel
food
intak
exercis
stress
ill
uptak
variabl
blood
stream
lack
excis
cpeptid
dose
form
etc
structur
variant
call
analog
recombin
technolog
allow
product
sever
variant
amino
acid
structur
detail
fig
without
biotechnolog
one
simpli
could
gain
kind
control
natur
molecul
obtain
today
even
extent
manmad
evolut
tailor
offset
effect
extern
drug
deliveri
one
look
simpl
insulin
sequenc
shown
referenc
without
gain
sens
immens
complex
inher
even
simpl
protein
structur
level
knowledg
pinpoint
control
protein
structur
thu
function
repres
truli
revolutionari
platform
clarifi
diseas
causat
well
develop
treatment
cure
howev
biolog
sideeffect
igg
protein
compris
two
heavi
chain
black
outlin
two
light
chain
blue
outlin
igg
heavi
chain
variabl
region
vh
constant
region
contain
three
domain
line
repres
hing
region
light
chain
variabl
vl
constant
region
cl
igg
molecul
divid
antigenbind
fragment
fab
empti
oval
fragment
crystalliz
region
fc
pink
oval
red
dot
repres
nlink
glycan
complextyp
b
composit
complextyp
nlink
glycan
igg
glycan
biantennari
heptasaccharid
core
solid
line
gray
block
variabl
extens
dash
line
abbrevi
f
fucos
n
glcnac
mannos
g
galactos
sialic
acid
enzym
glycosyltransferas
left
arrow
glycosidas
right
arrow
respons
addit
remov
specif
sugar
place
directli
underneath
sugar
linkag
kait
c
shade
robert
anthoni
cc
yet
fulli
understood
brought
increas
scrutini
mean
product
well
microstructur
variant
produc
biolog
product
process
concern
lifesav
therapi
come
fear
therapi
may
cut
short
due
drug
reaction
includ
allergylik
cytokin
induc
mount
adapt
immun
antibodi
respons
administ
protein
advers
respons
patient
driven
mani
chang
develop
control
biolog
product
process
includ
need
human
molecul
well
bring
realiz
small
chang
molecul
structur
glycosyl
stabil
aggreg
particul
bring
unwant
immun
reaction
discuss
detail
chap
short
size
biolog
molecul
enter
cell
degre
human
well
potenti
product
artifact
includ
aggreg
particul
host
cell
impur
creat
rang
expect
immun
respons
differ
class
biolog
molecul
understand
slow
bring
realiz
microbiolog
control
may
equal
immunolog
control
exclus
microbi
artifact
thu
presenc
potenti
hidden
microbi
artifact
includ
endotoxin
becom
close
scrutin
primari
structur
human
insulin
analogu
differ
highlight
number
earli
biolog
product
manufactur
began
see
manufactur
qualiti
would
improv
process
inherit
lvp
smd
manufactur
biolog
came
mani
addit
concern
associ
previous
routin
process
includ
protein
aggreg
silicon
stopper
coat
vial
exist
particl
subvis
rang
etc
highli
defin
condit
biolog
must
produc
led
assert
biolog
process
product
addit
process
impur
aris
product
express
system
must
remov
also
true
minut
differ
heterogen
product
protein
structur
especi
protein
glycosyl
therefor
biolog
product
process
finish
product
fulli
character
laboratori
manufactur
must
ensur
product
consist
qualiti
puriti
ensur
manufactur
process
remain
substanti
time
contrast
drug
manufactur
chang
manufactur
process
extens
analyz
finish
product
establish
manufactur
chang
live
system
use
produc
biolog
sensit
minor
chang
manufactur
process
small
process
differ
significantli
affect
natur
finish
biolog
importantli
way
function
bodi
ensur
manufactur
process
remain
time
biolog
manufactur
must
tightli
control
sourc
natur
start
materi
consist
employ
hundr
process
control
assur
predict
manufactur
outcom
overt
differ
exist
smd
manufactur
base
chemic
synthesi
eg
gemcitabin
mw
cisplatin
mw
growthbas
biolog
product
eg
trastuzumab
mw
adalimumab
mw
mode
action
four
drug
briefli
compar
figur
show
simplifi
manufactur
process
flow
common
biolog
monoclon
antibodi
associ
ich
qualiti
requir
due
complex
natur
limit
clinic
experi
biolog
chimer
fusion
protein
biosimilar
approv
high
level
character
demand
continu
develop
character
need
cover
protein
peptid
map
glycan
analys
util
stateoftheart
analyt
method
character
glycoform
liquid
chromatographymass
spectrometri
ms
capillari
electrophores
well
classic
electrophoret
chromatograph
method
play
increasingli
import
role
respect
baldo
process
control
biolog
complex
heat
labil
termin
steril
consist
nonsteril
process
growth
promot
upstream
well
ph
neutral
downstream
care
taken
control
microbi
ingress
via
bioburden
endotoxin
monitor
overview
biophorum
oper
group
bpog
detail
biopharmaceut
industri
produc
nonsteril
bulk
biolog
ie
drug
substanc
use
bioburden
control
process
accord
annex
steril
final
dosag
form
produc
accord
annex
mammalian
cell
mab
process
consist
upstream
downstream
process
upstream
oper
includ
protein
product
phase
manufactur
host
cell
grown
gener
product
molecul
primari
recoveri
centrifug
depth
filtrat
first
step
remov
unwant
product
compon
retain
product
molecul
captur
target
molecul
often
achiev
affin
chromatographi
hand
hand
biotechnolog
revolut
mechan
action
mani
biolog
base
upon
immunolog
scienc
explod
last
year
one
consid
janeway
proposit
exist
pattern
recognit
receptor
prr
molecular
immun
receptor
fit
microbi
pamp
explos
knowledg
come
sinc
term
myriad
receptor
control
affect
immun
interact
becom
appar
import
elabor
cell
surfac
signal
molecul
cssm
particularli
import
modul
immun
respons
conjunct
develop
manufactur
use
biolog
molecul
overst
therapeut
target
cssm
combin
develop
monoclon
antibodi
hybridoma
technolog
kohler
milstein
continu
elabor
antibodi
paratop
fit
variou
antigen
epitop
includ
human
receptor
effect
brought
fruition
paul
ehrlich
origin
magic
bullet
concept
detail
knowledg
work
mechan
larg
immuneact
biomolecul
monoclon
antibodi
integr
understand
function
magic
bullet
interact
therapeut
biomolecul
cssm
begin
affect
way
microbiolog
control
view
present
differ
larg
appreci
paradigm
shift
manipul
cssm
therapeut
control
subcellular
molecular
almost
atom
level
term
diseas
treatment
biolog
therapeut
action
often
gain
interact
protein
ligand
receptor
cssm
lymphocyt
cssm
surfac
includ
tlr
base
upon
human
genom
project
sequenc
annot
molecul
identifi
potenti
cssm
base
similar
transmembran
protein
structur
along
signatur
intracellular
extracellular
domain
zhu
yao
chen
refer
back
fig
differ
biolog
smd
exemplifi
compar
mechan
action
two
small
molecul
cancer
treatment
compoundsgemcitabin
cisplatinwith
two
biolog
mab
pertuzumab
trastuzumab
former
two
biolog
prevent
ligand
induc
dimer
later
disrupt
ligandindepend
complex
format
baldo
see
fig
mab
larg
molecul
specif
target
cssm
either
prevent
promot
costimulatorycoinhibitori
fulfil
function
import
specif
cancer
instanc
mode
action
biolog
contrast
small
molecul
schemat
represent
mechan
action
drug
pz
recogn
epitop
within
dimer
domain
thu
prevent
interact
activ
erbb
receptor
moreov
pz
recruit
natur
killer
cell
mediat
adcc
tki
act
tyrosin
kinas
activ
block
intracellular
signal
tz
bind
juxtamembran
portion
thu
prevent
receptor
cleavag
stimul
adcc
respons
receptor
degrad
endocytosi
complex
pz
pertuzumab
tz
trastuzumab
tki
tyrosin
kinas
inhibitor
adcc
antibodi
depend
cellular
cytotox
human
epiderm
growth
factor
receptor
erbb
erythroblast
leukemia
viral
oncogen
homolog
enter
cell
thu
larg
target
fast
grow
tissu
gemcitabin
nucleotid
analog
mimic
cystein
c
dnaatgc
curtail
replic
due
imperfect
mimick
nucleotid
action
cisplatin
differ
mode
action
similarli
disrupt
dna
replic
sinc
cancer
cell
fastest
grow
cell
appar
better
reason
cancer
cell
die
normal
cell
thu
smd
cancer
treatment
invas
enter
cancer
cell
also
healthi
cell
nonspecif
specif
molecular
target
dna
common
cell
prone
gener
resist
time
limit
window
posit
effect
gener
bring
unpleas
side
effect
new
biolog
drug
accord
barker
andrew
result
side
effect
signific
impact
patient
gut
toxic
immunosuppress
hair
loss
effect
limit
dose
chemotherapeut
given
overal
efficaci
achiev
mani
situat
thu
whilst
cytotox
chemotherapi
use
type
tumour
result
mani
common
solid
tumour
rel
disappoint
agent
effect
solid
tumour
better
toler
would
repres
major
step
forward
fight
cancer
advent
biolog
especi
mab
bind
variou
receptor
cssm
thought
activ
cancer
progress
greatli
improv
therapi
option
number
cancer
type
includ
target
breast
cancer
note
rel
size
target
receptor
mab
graphic
repres
wide
differ
wherea
molecul
size
dissimilar
kda
kda
respect
human
epiderm
growth
factor
receptor
transmembran
glycoprotein
receptor
tyrosin
kinas
involv
signal
transduct
pathway
lead
cell
growth
differenti
contrast
three
member
epiderm
growth
factor
receptor
famili
thought
orphan
receptor
ie
lack
ligand
howev
form
heterodim
relat
receptor
result
receptor
activ
enhanc
level
shown
correl
one
form
aggress
breast
cancer
precipit
develop
monoclon
antibodi
mab
trastuzumab
pertuzumab
take
fig
one
step
mazzucchelli
et
al
graphic
demonstr
develop
addit
treatment
form
truncat
immun
modul
sequenc
attach
nanoparticl
top
part
fig
emerg
trend
util
possibl
activ
part
antibodi
demonstr
left
right
also
explor
use
vlr
therapeut
candid
main
takeaway
figur
relev
discuss
incred
specif
b
variou
target
possibl
c
futureori
develop
novel
method
immun
modul
aim
specif
receptor
receptor
moieti
overview
variou
class
biolog
seven
major
class
enzym
hormon
peptid
drug
combin
singl
categori
describ
includ
exampl
drug
mechan
action
moa
descript
monoclon
antibodi
mab
mab
consist
three
major
class
includ
immun
stimul
ie
cancer
treatment
b
inflamm
autoimmun
suppress
c
miscellan
basket
molecul
includ
sever
novel
act
drug
treatment
asthma
anthrax
organ
transplant
rsv
infect
baldo
omalizumab
asthma
drug
act
bind
ige
antibodi
paratop
region
import
ige
bind
mast
cell
way
omalizumab
interfer
via
steric
hindranc
mast
cell
activ
includ
reduct
advers
allerg
type
respons
includ
anaphylaxi
suppress
immun
system
specif
biolog
treatment
autoimmun
diseas
also
lead
slightli
increas
occurr
rare
brain
cancer
caus
usual
latent
viru
enzym
hormon
glycoprotein
hormon
peptid
drugshuman
enzym
defici
includ
genet
disord
inborn
error
metabol
level
much
littl
affect
disord
certain
genet
acquir
disord
correct
suppli
enzym
via
recombin
product
correct
receptor
cssm
exampl
describ
discoveri
specif
recognit
phosphoryl
mannos
residu
mannos
receptormedi
uptak
lysosom
enzym
presenc
receptor
macrophag
demonstr
lysosom
enzym
need
specif
recogn
target
cell
insight
led
first
success
enzym
replac
therapi
ert
type
gaucher
diseas
occur
frequenc
birth
worldwid
make
preval
sphingolipid
storag
disord
gaucher
diseas
result
inborn
error
metabol
due
defici
lysosom
acid
glycoprotein
glucosylceramidas
acylsphingosin
glucohydrolas
cleav
glucosylceramid
glucocerebrosid
glucos
ceramid
enzym
substrat
wide
distribut
cell
membran
compon
absenc
glucocerebrosid
glycolipid
accumul
much
lysosom
cell
particularli
macrophag
cell
reticuloendotheli
system
background
glucocerebrosidas
prepar
human
placenta
market
use
revers
clinic
manifest
type
gaucher
diseas
target
patient
macrophag
sequenti
deglycosyl
expos
mannos
residu
imigluceras
recombin
deglycosyl
glucocerebrosidas
prepar
chines
hamster
ovari
cell
dna
technolog
soon
introduc
prove
least
clinic
effect
could
provid
pathogenfre
prepar
almost
unlimit
amount
soon
replac
predecessor
baldo
exampl
along
switch
animalderiv
insulin
recombin
human
insulin
show
vast
util
recombin
protein
rprotein
compar
harvest
natur
form
nprotein
hormon
peptid
drug
includ
insulin
glucagon
human
growth
hormon
vasopressin
parathyroid
hormon
glycoprotein
hormon
includ
folliclestimul
hormon
thyroid
stimul
hormon
asid
use
rprotein
human
insulin
bring
greater
exact
specif
treatment
wherea
relianc
upon
anim
extract
protein
time
consum
labori
made
less
desir
drug
especi
microbiolog
adventiti
contamin
control
vantag
vaccin
harmless
biolog
prepar
made
infecti
agent
intend
stimul
immun
system
produc
longlast
immun
protect
import
diseas
remain
protect
via
vaccin
includ
aid
tuberculosi
malaria
prion
diseas
cancer
vaccin
also
develop
mab
develop
immun
treatment
altern
longact
vaccin
infect
rsv
subunit
vaccin
view
safer
protein
gene
clone
express
use
specif
antigen
revert
diseasecaus
state
attenu
organ
exampl
hepat
b
vaccin
use
surfac
protein
aid
prevent
hepat
associ
liver
cancer
dna
vaccin
also
develop
encod
specif
antigen
protein
inject
interestingli
dna
vaccin
cpg
bacteri
sequenc
includ
adjuv
type
speak
modern
use
tlr
activ
pamp
adjuv
parallel
inclus
concern
impuiritycontamin
adjuv
beyond
doubt
advent
sequenc
render
microbi
genom
readili
access
utmost
import
vaccinolog
allow
highli
ration
identif
vaccin
antigen
mani
novel
vaccin
current
develop
thu
base
protein
peptid
predict
comput
databas
screen
antigen
librari
although
advanc
postgenom
era
enabl
design
highli
pure
safe
simpl
vaccin
challeng
emerg
parallel
includ
inher
lack
immunostimulatori
properti
protein
peptid
vaccin
adjuv
therefor
consid
key
compon
modern
vaccinolog
sinc
provid
necessari
help
enhanc
immun
respons
one
may
pick
inher
contradict
foreign
protein
microb
virion
produc
recombinantli
purifi
often
immunogen
thu
adjuv
essenc
contamin
must
ad
wherea
purifi
human
recombin
protein
base
igg
scaffold
manufactur
recombin
protein
often
come
immunolog
side
effect
earli
vaccin
need
adjuv
contain
everyth
kitchen
sink
microbiolog
speak
vaccin
becom
purifi
becom
less
immunogen
unwant
side
effect
may
come
use
kill
whole
microorgan
ad
ambigu
immun
irrit
therefor
today
choic
adjuv
sophist
effort
contain
effort
also
attempt
stimul
appropri
immun
respons
pathway
match
specif
immun
mechan
action
diseas
vaccin
see
fig
antigen
inher
immunogen
virtual
vaccin
requir
adjuv
form
endogen
exogen
without
compon
engag
either
innat
immun
cell
addit
receptor
lymphocyt
complement
receptor
nonadjuv
highlypurifi
antigen
induc
toler
rather
immun
antigen
certain
toxin
capabl
induc
antibodi
respons
administ
without
adjuv
immunogen
nontox
deriv
toxin
develop
adjuv
cholera
toxin
ct
e
coli
enterotoxin
lt
review
first
scientif
report
exogen
adjuv
deliber
ad
vaccin
less
centuri
old
come
gaston
ramon
substanc
ad
vaccin
enhanc
immun
respons
complex
poorli
defin
includ
tapioca
starch
agaros
earli
adjuv
howev
trigger
inflamm
subsequ
enhanc
vaccinespecif
lymphocyt
respons
adjuvant
scenario
bystand
effect
signific
amount
wast
inflamm
quot
nm
valiant
novarti
vaccin
defin
excess
innat
immun
respons
result
reactogen
partial
contribut
adapt
immun
respons
coagul
factor
mammalian
blood
coagul
complex
process
interact
mani
factor
contrast
greatli
simplifi
limulu
coagul
process
queen
victoria
born
hemophilia
thu
diseas
known
long
blood
system
factor
character
two
type
hemophilia
occur
due
lack
clot
factor
viii
hemophilia
b
occur
due
lack
clot
factor
ix
afflict
typic
inherit
one
parent
x
chromosom
nonfunct
gene
thu
disproportion
affect
male
dozen
blood
clot
factor
produc
recombinantli
includ
factor
viia
viii
ix
ix
fc
fusion
protein
xiii
addit
recombin
form
also
mani
form
purifi
pool
human
plasma
recombin
natur
form
may
includ
sever
hypersensit
fever
respons
mechan
suppli
specif
enzym
clot
pathway
mere
suppli
miss
link
function
enzym
break
chain
event
ie
proteas
cascad
necessari
properli
coagul
blood
cytokinesar
produc
cell
immun
system
gener
thought
signal
act
local
upon
cssm
versu
hormon
act
greater
distanc
bodi
howev
system
effect
also
result
addit
local
effect
cytokin
includ
sepsi
categori
includ
drug
use
cytokin
cytokin
receptor
antagonist
modul
immun
respons
includ
chemokin
interferon
interleukin
lymphokin
tumor
necrosi
factor
tnf
hormon
growth
factor
anoth
class
biolog
therapi
june
approv
cytokin
antagonist
biolog
therapeut
drug
includ
interferon
interleukin
erythropoietin
bone
morphogen
protein
receptor
antagonist
il
inf
tnf
anakinra
exampl
bind
receptor
thu
block
receptor
system
import
govern
activ
cartilag
degrad
bone
resorpt
overview
action
variou
cytokin
given
tisoncik
et
al
interferonsregul
innat
immun
activ
antivir
properti
antiprolif
effect
interleukinsgrowth
differenti
leukocyt
recruit
mani
proinflammatori
chemokinescontrol
chemotaxi
leukocyt
recruit
mani
proinflammatori
colonystimul
factorsstimul
hematopoiet
progenitor
cell
prolifer
differenti
tumor
necrosi
factorproinflammatori
activ
cytotox
lymphocyt
fusion
chimer
proteinstwo
differ
protein
uniqu
function
fuse
form
singl
therapeut
protein
etanercept
fusion
protein
use
fc
portion
igg
antibodi
link
ligandbind
portion
tnf
receptor
bind
fusion
molecul
tnf
receptor
prevent
interact
receptor
tnf
cytokin
thu
reduc
associ
inflammatori
respons
rheumatoid
arthriti
autoimmun
diseas
tnf
receptor
bind
shown
fig
cell
therapyth
use
igg
fragment
well
whole
immun
cell
ie
cell
genet
modifi
consist
taken
individu
return
individu
autolog
taken
one
return
mani
allogen
earliest
cell
type
taken
return
bone
marrow
stem
cell
transplant
promis
new
cancer
treatment
base
upon
modif
cell
receptor
cell
sensit
neoplasm
interest
differenti
cell
grown
administr
grown
produc
recombin
drug
cell
rproduct
grown
discard
often
known
accru
genet
aberr
time
cho
natur
mode
growth
cell
cultur
howev
introduct
whole
cell
must
contain
cell
maintain
proper
genet
structur
phenotyp
genotyp
even
karyotyp
must
contain
cell
cultur
media
rapidli
emerg
immunotherapi
approach
call
adopt
cell
transfer
act
collect
use
patient
immun
cell
treat
cancer
sever
type
act
see
act
til
tcr
car
thu
far
one
advanc
furthest
clinic
develop
call
car
tcell
therapi
two
car
tcell
therapi
approv
food
drug
administr
fda
one
treatment
children
acut
lymphoblast
leukemia
adult
advanc
lymphoma
nevertheless
research
caution
mani
respect
still
earli
day
car
cell
form
act
includ
question
whether
ever
effect
solid
tumor
like
breast
colorect
cancer
biolog
present
special
instanc
regard
studi
effect
biomolecul
preclin
clinic
studi
follow
relev
categori
list
kingham
et
al
relev
speciesoften
biolog
display
reaction
specif
variou
nonhuman
speci
therefor
must
studi
relev
speci
alway
common
one
also
seen
extend
tissu
specif
immunogenicityth
common
elicit
immun
respons
effect
must
consid
biolog
drug
often
clinic
develop
program
must
includ
assess
immunogen
typic
issu
small
molecul
drug
manufactur
process
chang
scrutin
even
clinic
stage
sinc
drug
affect
process
chang
manufactur
fda
decid
whether
sponsor
perform
addit
studi
ensur
chang
deleteri
product
regulatori
vantag
biolog
drug
requir
submiss
biolog
licens
applic
bla
wherea
new
drug
requir
new
drug
applic
nda
biolog
design
also
convey
extend
legal
protect
term
intellectu
properti
right
unit
state
biolog
product
subject
differ
premarket
pathway
differ
intellectu
properti
protect
product
regul
drug
wherea
biolog
product
must
licens
pursuant
biolog
licens
applic
bla
show
safe
pure
potent
sponsor
nonbiolog
drug
must
submit
new
drug
applic
nda
show
drug
safe
effect
certain
new
biolog
product
receiv
year
data
protect
new
drug
receiv
year
protect
biolog
drug
legisl
also
provid
differ
scheme
resolv
patent
issu
regard
entri
followon
product
thu
determin
whether
product
meet
definit
biolog
product
enorm
import
kingham
along
distinct
protein
consist
amino
acid
smaller
classifi
peptid
drug
biolog
accord
timmi
combin
regul
requir
fda
approv
manufactur
process
facilitieslet
alon
actual
drugthi
complex
ensur
significantli
expens
creation
process
common
tradit
chemic
drug
estim
place
cost
creat
manufactur
facil
new
biolog
drug
exclud
materi
bring
new
biolog
market
cost
estim
billion
intuit
increas
cell
express
increas
yield
therapeut
protein
also
increas
impur
remov
due
increas
mass
cell
thu
weight
chromatographi
remov
method
host
cell
protein
nucleic
acid
remov
increas
shown
duel
load
product
cell
refus
sit
apex
upstream
downstream
process
flow
fig
mimet
actual
microbiolog
byproduct
cell
constitu
rather
process
constitu
may
immun
activ
bodi
surveil
immun
system
treat
microbi
natur
recur
pattern
exampl
may
mimic
viruslik
particl
view
immun
system
mimet
shown
includ
protein
aggreg
emuls
silicon
coat
stopper
vial
particul
even
subvis
particul
control
mimet
littl
concern
manufactur
lvp
smd
rel
larg
particul
host
cell
protein
hcp
impur
determin
hcp
remov
applic
biolog
produc
live
cell
cell
grow
produc
therapeut
protein
also
produc
substanc
simpli
aliv
reproduc
etc
may
includ
excret
exotoxin
well
intrins
makeup
dna
rna
porin
flagellin
endotoxin
etc
residu
must
remov
via
variou
chromatographi
step
may
includ
endotoxin
larg
amount
e
coli
use
express
system
import
hcp
impur
control
given
wang
et
al
hcp
constitut
major
group
processrel
impur
drug
product
risk
associ
hcp
primarili
immunogen
hcp
complex
mixtur
divers
physiochem
immunolog
properti
almost
hcp
carri
clinic
safeti
risk
foreign
protein
due
potenti
elicit
immun
respons
human
addit
hcp
also
act
adjuv
enhanc
immun
respons
drug
product
certain
hcp
proteolyt
activ
also
affect
drug
product
stabil
efficaci
adequ
remov
inactiv
hcp
potenti
affect
safeti
efficaci
aspect
given
drug
product
nonproduct
protein
detect
thu
determin
remov
typic
polyclon
antibodi
rais
product
express
system
manufactur
minu
drug
protein
subsequ
batch
batch
run
determin
set
librari
polyclon
antibodi
use
determin
level
extent
remov
success
via
elisa
test
identif
specif
protein
marker
known
suspect
immunogen
also
accru
nucleic
acid
remov
accord
wang
et
al
biolog
product
uniqu
aspect
concern
remov
nucleic
acid
particularli
residu
dna
residu
dna
rdna
compris
deoxyribonucl
acid
dna
fragment
longer
length
molecul
origin
host
organ
may
present
sampl
recombin
biolog
process
although
similar
basic
structur
base
pair
unit
rdna
may
exist
differ
size
physic
form
interest
measur
rdna
recombin
product
base
primarili
demonstr
effect
purif
manufactur
also
hypothet
concern
rare
case
depend
host
express
system
dna
sequenc
may
potenti
infecti
oncogen
eg
hiv
viru
ra
oncogen
respect
genom
dna
microbi
sourc
hand
could
add
risk
immunogen
target
recombin
protein
express
due
high
cpg
content
unmethyl
dna
sequenc
reason
necessari
manufactur
show
clearanc
dna
throughout
product
process
confirm
low
level
final
drug
substanc
use
appropri
specif
quantit
analyt
method
common
methodolog
rdna
quantit
use
current
realtim
polymeras
chain
reaction
rtpcr
robust
proven
technolog
like
rdna
quantit
method
specif
rtpcr
limit
sequenc
primer
direct
beta
glucan
fungal
cell
wall
constitu
especi
beta
glucan
come
consid
mani
innat
immun
respons
modul
impur
iirmi
therefor
remov
preclud
biolog
manufactur
process
process
develop
seen
follow
effort
multiprong
approach
manag
betaglucan
contamin
downstream
process
control
raw
materi
filtrat
chargemodifi
nylon
membran
filter
develop
downstream
process
minim
betaglucan
impur
gmpmanufactur
therapeut
antibodi
note
beta
glucan
impur
fungal
residu
found
byproduct
breakdown
cellulos
filter
potenti
contamin
pharmaceut
product
origin
cellulosebas
filter
raw
materi
use
pharmaceut
process
also
show
falseposit
endotoxin
test
repres
falseposit
result
glucan
interfer
bet
quantit
bet
bet
standard
includ
see
chap
overview
detect
product
rational
includ
routin
test
rather
preclud
process
develop
unlik
crop
via
contamin
fungi
wherea
endotoxin
gram
neg
bacteria
easili
prolifer
much
like
present
due
either
cellulos
filter
usag
breakdown
cellulos
filter
switch
noncellulos
filter
b
fungal
sugar
present
raw
materi
also
preclud
advent
biolog
soon
becam
appar
would
differ
rule
biolog
given
propens
immunolog
respons
biolog
given
use
variou
express
system
growthbas
process
need
remov
hostcel
impur
monitor
nonsteril
process
requir
demonstr
hold
time
studi
prove
process
condit
allow
microbiolog
overgrowth
addit
much
new
term
microbiolog
control
strategi
chap
shen
describ
method
use
remov
endotoxin
impur
contamin
good
make
distinct
impur
potenti
residu
compon
upstream
product
express
system
cho
cell
e
coli
yeast
plant
etc
potenti
contamin
aris
downstream
nonsteril
process
ingress
ie
bioburden
rout
includ
endotoxin
upstream
express
system
gramneg
organ
e
coli
downstream
via
waterbas
buffer
downstream
process
gramneg
like
form
grow
nonsteril
ph
neutral
aqueou
solut
issu
bioburden
biolog
view
complianc
perspect
outcom
specif
inspect
find
accord
bioburden
rare
happen
except
regul
show
howev
except
profici
capabl
manufactur
automat
transfer
other
better
other
view
fda
warn
letter
multipl
lot
drug
substanc
releas
unaccept
high
level
bioburden
final
purif
step
microbi
limit
establish
process
step
result
show
high
bioburden
level
cfuml
harvest
unprocess
bulk
sublot
lot
redact
lot
redact
exceed
establish
action
limit
bioburden
bpog
recommend
inprocess
biolog
bioburden
investig
materi
numer
count
tntc
specif
context
current
discuss
also
seem
overli
stringent
tntc
result
inprocess
bioburden
sampl
automat
result
action
level
specif
oo
requir
investig
cost
bioburden
excurs
biolog
manufactur
substanti
westman
summar
estim
financi
impact
tabl
signific
paradigm
chang
manufactur
could
signific
posit
impact
mcc
includ
use
singleus
bioreactor
contain
new
trend
address
implement
singleus
bioreactor
system
advantag
lower
capit
invest
oper
cost
flexibl
improv
product
schedul
higher
process
replic
applic
gmp
manufactur
avail
l
scale
differ
design
singleus
reactor
avail
wave
orbit
shaken
pneumat
mix
stir
tank
bioreactor
elimin
need
clean
steril
thu
significantli
reduc
contamin
rate
biolog
manufactur
mani
bioburdenendotoxin
sampl
expect
outlin
bioburden
endotoxin
sampl
expect
monoclon
antibodi
recombin
protein
drug
given
biophorum
oper
group
bpog
detail
biopharmaceut
industri
produc
nonsteril
bulk
biolog
ie
drug
substanc
use
bioburden
control
process
accord
annex
steril
final
dosag
form
produc
accord
annex
mammalian
cell
mab
process
consist
upstream
downstream
process
upstream
oper
includ
protein
product
phase
manufactur
host
cell
grown
gener
product
molecul
primari
recoveri
centrifug
depth
filtrat
first
step
remov
unwant
product
compon
retain
product
molecul
captur
target
molecul
often
achiev
affin
regard
recommend
arriv
bpog
group
follow
talk
point
relev
mcc
biolog
product
sinc
bpog
repres
mani
pharma
compani
name
paper
consid
current
pharma
consensu
follow
point
deriv
biophorum
publish
document
condens
overview
therefor
specif
detail
go
sourc
document
recommend
sampl
point
includ
paraphras
breviti
follow
media
prepar
appropri
number
batch
scale
base
statist
analysi
andor
risk
assess
test
bioburdenendotoxin
prior
filtrat
steril
media
filter
buffer
perform
bioburdenendotoxin
appropri
number
batch
scale
final
diafiltr
formul
buffer
endotoxin
test
recommend
prior
use
nonfilter
buffer
freshli
prepar
use
soon
possibl
bioburden
endotoxin
samplingtest
nonfilt
buffer
recommend
prior
transfer
next
bioreactor
bioburden
sampl
may
test
kept
backup
clarifi
harvest
pool
filter
unfilt
test
bioburden
endotoxin
batch
prior
start
follow
process
step
evalu
column
ufdf
perform
perform
bioburdenendotoxin
test
appropri
number
batch
scale
endotoxinbioburden
test
protein
pool
filter
unfilt
end
chromatographi
ufdf
oper
resin
storag
condit
test
bioburden
take
bioburden
endotoxin
sampl
final
bulk
drug
substanc
post
filtrat
plate
count
recoveri
cfu
dilut
sampl
report
tntc
inprocess
bioburden
sampl
result
action
level
oo
requir
investig
unlik
nonsteril
drug
manufactur
process
environ
often
hostil
microbi
growth
includ
addit
preserv
manufactur
biolog
requir
growth
medium
upstream
enhanc
bacteri
growth
process
buffer
downstream
perform
assess
bioburden
action
level
excurs
advers
trend
note
question
ask
includ
follow
organ
recov
disinfect
procedur
effect
remov
recov
organ
toxin
andor
microbi
byproduct
organ
produc
releas
stage
process
excurs
occur
downstream
purif
step
perform
organ
recov
purif
step
valid
remov
bioburden
data
support
clearanc
possibl
microbi
byproduct
connect
bioburden
excurs
upstream
downstream
process
organ
seen
previou
lot
long
product
held
step
excurs
temp
ph
chang
manufactur
process
eg
equip
prior
excurs
potenti
impact
could
recov
organ
manufactur
protein
impact
microbi
byproduct
product
toxin
patient
product
safeti
ipc
result
within
histor
trend
ds
meet
releas
specif
inform
gather
studi
conduct
investig
pose
question
sinc
endotoxin
come
bioburden
assum
none
coli
express
system
ca
nt
one
test
bioburden
endotoxin
made
appar
bpog
assess
variou
process
step
filtrat
bioburden
occur
thu
remov
whole
cell
leav
cumul
amount
nonviabl
microbi
residu
includ
especi
endotoxin
make
limulusbas
test
critic
perform
support
bioburden
result
may
step
step
begin
zero
serial
fashion
way
limulusbas
test
necessari
perform
conjunct
bioburden
test
depict
fig
describ
detail
bioburden
endotoxin
routin
sampl
manufactur
expect
howev
addit
sinc
specif
biolog
manufactur
process
specif
time
process
step
hold
time
temperatur
environment
definit
specif
defin
paramet
must
shown
inprocess
control
downstream
process
bioburden
filter
process
step
process
stepwherea
smaller
constitu
includ
especi
endotoxin
due
size
biolog
molecul
thu
process
requir
confirm
via
limulusbas
test
curtail
microbi
growth
low
level
excurs
occur
shown
empir
perform
ht
condit
specif
process
along
identifi
potenti
point
microbi
ingress
ht
help
defin
overal
control
strategi
bioburden
endotoxin
anyth
better
use
biotechnolog
cure
diseas
may
faster
greater
volum
decreas
cost
increas
safeguard
given
biolog
manufactur
mani
way
still
infanc
ampl
avenu
explor
increas
safeti
throughput
util
biolog
product
singl
exampl
given
previou
one
mention
singleus
bioreactor
chang
express
system
gain
increas
protein
product
shorter
time
expect
reduc
occurr
impur
emalfarb
relat
effort
improv
capac
product
switch
current
cho
base
express
use
fungu
call
myceliophthora
thermophilia
drug
platform
util
fungal
strain
alreadi
approach
gram
per
liter
seven
day
alreadi
far
excess
industri
averag
approxim
gram
per
liter
day
high
product
fungal
strain
equival
amount
drug
may
abl
synthes
within
bioreactor
current
made
use
cho
two
tank
advantag
fungu
could
hold
capit
expenditur
oper
cost
clear
author
also
point
much
higher
yield
possibl
also
leav
less
impur
remov
sinc
risk
viral
contamin
thu
remov
two
purif
step
associ
tradit
cho
purif
say
fungal
strain
alreadi
receiv
gener
recogn
safe
design
fda
platform
produc
use
proprietari
strain
myceliophthora
thermophilia
similar
strain
shown
fig
plantbas
express
also
explor
may
produc
similar
express
advantag
reason
exist
biolog
lifesav
drug
thu
import
state
shortcom
aton
util
patient
howev
also
seem
import
understand
histor
discontinu
exist
modern
biolog
histor
anteced
drug
drug
manufactur
mcc
perspect
given
miracul
earli
histori
biolog
shock
success
includ
rabi
smallpox
polio
vaccin
well
earli
anim
insulin
perhap
surpris
miracul
advanc
gain
biotechnolog
revolut
class
biolog
present
may
includ
dozen
lifesav
qualiti
lifeenhanc
molecul
treat
wide
rang
afflict
lame
walk
blind
see
infect
heal
healthi
shield
futur
diseas
malign
fall
away
genet
lack
made
whole
full
fruit
biotechnolog
revolut
continu
amaz
downsid
lifesav
lifechang
design
unfortun
must
stop
therapi
due
advers
reaction
improv
specif
drug
advers
event
profil
therefor
human
busi
compon
attempt
reduc
advers
reaction
help
patient
continu
therapi
well
help
drug
manufactur
present
fewer
side
effect
competit
marketplac
flipsid
gain
power
cure
diseas
least
vastli
increas
util
therapi
potenti
denial
treatment
rather
worstcas
exampl
consequ
termin
biolog
therapi
due
advers
event
develop
antibodi
administ
recombin
protein
exampl
given
pure
red
cell
aplasia
prca
caus
neutral
antibodi
epoetin
crossreact
natur
erythropoietin
produc
rapid
declin
hemoglobin
concentr
sever
anemia
low
reticulocyt
count
almost
total
absenc
red
cell
precursor
baldo
extrem
advers
case
refer
break
toler
self
format
natur
antibodi
recombin
protein
subsequ
come
imperil
continu
exist
bodi
natur
protein
also
attack
recombin
mean
ident
instanc
discontinu
lifesav
drug
need
case
endstag
renal
diseas
patient
catastroph
chapter
discuss
format
antibodi
neutral
ada
nab
develop
patient
use
treat
sc
im
respect
attempt
circumv
lack
toler
recombin
molecul
share
natur
amino
acid
sequenc
patient
develop
neutral
drug
antibodi
nda
put
receptor
anoth
protein
scaffold
amino
acid
sequenc
homolog
natur
protein
howev
case
erythropoietin
use
nonrel
peptid
mimet
caus
patient
experi
differ
set
advers
respons
includ
anaphylaxi
necessit
voluntari
remov
new
replac
drug
market
sever
patient
death
fda
acquir
vial
pull
medicin
associ
respons
presenc
subvis
particl
manufactur
vial
rel
vial
use
clinic
trial
upon
approv
base
describ
chap
though
rare
patient
also
succumb
antidrug
antibodi
drugassoci
side
effect
basic
immunolog
knowledg
necessari
follow
develop
trend
specif
biolog
microbiolog
control
immunolog
background
establish
chap
focus
simpl
model
without
basic
immunolog
knowledg
appreci
ongo
seachang
current
endotoxin
pyrogenonli
model
endotoxin
control
supplant
control
includ
ad
immun
context
immunolog
precept
specif
monoclon
antibodi
antibodi
gener
gener
therefor
appli
natur
polyclon
therapeut
monoclon
antibodi
natur
antibodi
produc
plasma
cell
deriv
activ
b
lymphocyt
paratop
complementarydetermin
region
cdr
antibodi
bind
antigen
amino
acid
sequenc
end
antibodi
fab
produc
hope
anticip
fit
antigen
epitop
epitop
consist
amino
acid
sequenc
microbi
antigen
antibodi
paratop
bind
antigen
one
b
cellplasma
cell
produc
one
antibodi
specif
paratop
type
secret
solubl
antibodi
cell
match
membran
bound
antibodi
act
receptor
b
cell
million
differ
cdrparatop
result
somat
nongerm
line
encod
rearrang
v
j
gene
germlin
encod
theori
gene
rearrang
could
produc
differ
antibodi
sinc
somat
rearrang
paratop
germlin
encod
intend
detect
structur
microb
may
even
develop
yet
next
year
influenza
viru
surfac
protein
exampl
call
anticipatori
structur
contrast
germlin
encod
nonclon
receptor
tolllik
receptor
fit
precis
conserv
microbi
structur
complex
detect
endotoxin
exampl
nonclon
receptor
fc
effector
end
antibodi
bind
specif
cell
type
fulfil
dictat
dual
fab
antigen
bind
structur
exampl
fc
receptor
provid
handl
phagocytosi
antibodi
attach
complement
fab
end
differ
mab
natur
gener
antibodi
monoclon
antibodi
contain
singular
paratopebind
sequenc
clone
cultur
mani
ident
copi
bind
specif
target
epitop
consid
common
protein
insulin
antigen
deriv
mammal
man
ie
anim
insulin
protein
amino
acid
shown
contain
potenti
antigen
epitop
antibodi
variabl
amino
acid
bind
region
defin
mani
overlap
group
amino
acid
thu
antibodi
may
fit
mani
potenti
paratop
shown
figur
b
paratop
defin
singl
complementari
epitop
rather
present
certain
molecular
characterist
bind
antigen
site
vari
affin
antibodi
bind
cleft
fig
show
antigen
squeez
two
arm
singl
fab
nomenclatur
scientif
name
mab
systemat
design
one
view
molecul
attribut
simpli
name
suffix
includ
human
zumab
human
umab
chimer
ximab
design
tabl
fig
templeton
moehl
call
antibodi
structur
dimer
dimer
two
heavi
h
chain
two
light
l
chain
antigen
recognit
capabl
lie
variabl
head
region
hl
pair
overal
structur
mab
given
igg
scaffold
shown
antigen
bind
site
determin
monoclon
antibodi
stem
suffix
mab
uniqu
prefix
special
mean
use
identifi
individu
product
fig
fit
scorpion
toxin
red
make
contact
six
cdr
loop
h
chain
green
l
chain
blue
author
describ
egg
insert
smallend
first
egg
cup
basket
around
toxin
repres
molecular
surfac
protein
mesh
style
surfac
around
fab
antibodi
render
transpar
solid
templeton
moehl
specif
amino
acid
sequenc
variabl
light
v
l
variabl
heavi
v
h
chain
wherea
constant
c
region
subject
somat
v
j
gene
rearrang
interest
even
variabl
region
conserv
constant
sequenc
variabl
segment
call
framework
residu
fr
make
v
h
v
l
chain
exampl
natur
har
chao
accomplish
someth
set
hardcod
structur
like
tlr
could
socal
fr
defin
posit
paratop
cdr
import
maintain
overal
structur
antibodi
bind
capabl
extrem
variabl
allow
take
entir
molecul
would
nt
maintain
antibodi
join
light
heavi
chain
form
space
arm
antibodi
call
antibodi
bind
cleft
antibodi
bind
site
see
fig
given
constant
structur
scaffold
util
specif
monoclon
antibodi
come
small
set
six
three
arm
antibodi
fab
cleft
region
contain
fraction
highli
rearrang
hypervari
sequenc
number
amino
acid
per
region
small
thu
typic
includ
perhap
amino
acid
residu
figur
show
mani
disulfid
bridg
yellow
form
cystein
residu
serv
hold
massiv
protein
structur
one
coher
function
unit
characterist
shape
also
show
cdr
paratop
function
c
linear
genet
produc
amino
acid
sequenc
bottom
common
box
diagram
antibodi
structur
well
b
fold
form
protein
cdr
typic
sit
linearli
next
one
anoth
figur
show
area
heterogen
associ
monoclon
antibodi
product
specif
individu
drug
mode
action
mab
bind
antigen
receptor
made
seen
fig
b
detail
four
differ
antiegfr
mab
differ
method
determin
cdr
sequenc
give
differ
estim
endotoxin
cours
microbi
byproduct
come
bioburden
process
impur
product
manufactur
e
coli
gnb
rochegenentech
develop
microbiolog
risk
assess
process
case
case
assess
bioburden
excurs
ccab
biolog
drug
manufactur
risk
microbi
contamin
real
biolog
product
sinc
endotoxin
pamp
associ
contamin
risk
assess
done
use
varieti
rational
number
differ
pamp
type
concern
includ
also
exotoxin
concern
smd
typic
chemic
synthes
risk
microbi
contamin
limit
final
product
mani
biolog
manufactur
step
eg
protein
purif
condit
formul
occur
nonsteril
condit
aqueou
system
ambient
temperatur
substanti
neutral
ph
condit
make
largescal
product
biolog
suscept
microbi
contamin
investig
microbi
excurs
must
adequ
assess
impact
product
qualiti
patient
safeti
prior
make
decis
regard
lot
releas
develop
success
microbi
control
strategi
largescal
product
biolog
base
risk
assess
ensur
endtoend
microbi
control
process
adequ
prevent
detect
risk
assess
requir
review
microbi
qualiti
direct
materi
util
wfi
process
gase
etc
individu
step
within
seri
unit
oper
constitut
ds
dp
manufactur
process
step
assess
evalu
processoper
condit
exist
control
regard
equip
manufactur
environ
personnel
prevent
control
effect
control
minim
microbi
contamin
goal
prevent
ingress
prolifer
process
equip
product
addit
exist
microbi
detect
control
assess
ensur
provid
continu
verif
microbi
prevent
control
work
intend
detect
control
consist
bioburden
endotoxin
test
establish
limit
sampl
obtain
defin
process
step
critic
process
step
eg
product
cultur
ds
accept
bioburden
limit
extrem
low
valid
bioburden
result
exceed
accept
criteria
would
lead
reject
batch
activ
pharmaceut
ingredi
biolog
product
usual
heat
sensit
therefor
filtrat
use
membran
pore
size
rang
size
method
choic
bioburden
reduct
termin
steril
filtrat
effect
remov
intact
microbi
cell
product
process
allow
remov
subcellular
structur
bacteria
fungi
copurifi
product
subcellular
structur
like
microbi
toxin
socal
pathogen
associ
molecular
pattern
pamp
ie
endotoxin
lipopeptid
lipoprotein
flagellin
bacteri
fungal
dna
cell
wall
polysaccharid
potenti
lead
toxic
allerg
inflammatori
respons
human
addit
copurifi
extracellular
proteas
endoglycosidas
potenti
lead
product
degrad
modif
word
bioburden
contamin
nonsteril
process
intermedi
repres
risk
even
filtrat
even
drug
substanc
drug
product
specif
met
key
aspect
ccab
seen
fig
broad
method
estim
contamin
level
fig
specif
pamp
contamin
calcul
level
given
worstcas
exampl
appendix
follow
methodolog
use
von
wintzingerod
determin
worst
case
potenti
contamin
per
variou
cell
type
biolog
rememb
sinc
biolog
grown
defin
media
rather
sole
waterbas
manufactur
combin
synthet
api
smd
nongram
neg
also
concern
preclus
method
method
use
determin
possibl
extent
variou
contamin
type
given
base
publish
data
rochegenentech
intern
proteom
studi
hypothet
amount
critic
microbiolog
byproduct
per
drug
dosag
calcul
follow
see
appendix
specif
recommend
base
worstcas
calcul
known
potent
pamp
toxin
second
sourc
inform
biolog
risk
assessmentcontrol
strategi
come
european
biopharmaceut
enterpris
ebe
concept
paper
control
raw
materi
annex
tabl
list
relev
nonexhaust
regulatori
guidanc
raw
materi
qc
shown
appendix
ii
endotoxin
test
laboratori
awar
potenti
hidden
endotoxin
protein
solut
given
rather
long
histori
occurr
even
given
expert
method
remov
erridg
put
togeth
good
summari
histori
immunolog
perspect
rather
microbiolog
perspect
includ
pamp
possibl
experiment
reagent
may
contamin
bacteri
endotoxin
lp
consider
research
immun
mediat
decad
inde
perceiv
immunolog
properti
sever
molecul
found
subsequ
result
endotoxin
contamin
frequent
result
use
recombin
protein
express
e
coli
use
studi
summar
tabl
shown
view
concern
howev
studi
potenti
endogen
tlr
ligand
use
altern
prepar
techniqu
exampl
studi
use
commerci
sourc
reagent
gift
research
use
reagent
prepar
primari
tissu
includ
blood
five
examin
recombin
protein
express
mammalian
system
thu
establish
view
studi
list
tabl
like
use
reagent
littl
opportun
microbi
contamin
evid
suggest
caution
may
requir
interpret
result
experi
use
control
methodolog
exampl
well
establish
lal
assay
easili
confound
presenc
molecul
bind
lp
inde
lbp
bactericidalpermeabilityinduc
protein
shown
complet
prevent
abil
lal
assay
detect
lp
thu
possibl
lp
content
mani
propos
ligand
could
greatli
underestim
ligand
capac
bind
lp
moreov
lal
assay
abl
detect
lipopeptid
contamin
notabl
consider
almost
half
report
suggest
propos
agent
stimul
signal
erridg
epistemolog
studi
know
think
know
merriam
webster
studi
theori
natur
ground
knowledg
especi
refer
limit
valid
name
know
protein
solut
free
endotoxin
protein
may
bind
thu
mask
endotoxin
limulusbas
test
know
releas
bound
pair
measur
b
understand
preclud
condit
bring
bind
concern
section
exemplifi
fig
particip
group
expert
domain
howev
knowledg
gap
form
two
domain
imped
commun
therefor
oper
perform
circular
argument
whether
endotoxin
process
seen
remain
hidden
problem
detect
want
assum
appli
limulusbas
test
dispos
lack
detect
equal
lack
occurr
endotoxin
yet
studi
petsch
et
al
demonstr
alway
case
particularli
cation
protein
tri
numer
method
unsuccess
tri
recov
spike
natur
endotoxin
filtrat
rang
biolog
drug
product
solut
includ
initi
proteas
digest
method
best
bunch
recov
spike
howev
end
work
use
proteinas
k
fig
knowledg
gap
may
form
manufactur
knowledg
complex
remov
method
laboratori
knowledg
limulusbas
test
method
potenti
gap
knowledg
avail
bind
statu
endotoxin
includ
isoelectr
point
protein
sampl
taken
sent
lab
test
digest
recoveri
treatment
break
protein
dislodg
endotoxin
could
lal
detect
ad
spike
amount
case
endotoxinprotein
bind
caus
seriou
problem
cation
pharmaprotein
assay
endotoxin
case
lal
assay
appropri
determin
absolut
amount
residu
endotoxin
ie
biolog
risk
product
petsch
et
al
laboratori
method
avail
ensur
protein
bound
endotoxin
test
purpos
provid
need
orthogon
check
protein
solut
prior
limulusbas
test
must
emphas
routin
test
process
solut
alway
detect
proteinbound
endotoxin
without
altern
method
treatment
show
specif
process
solut
question
contain
proteinbound
endotoxin
method
potenti
list
use
proteinas
k
per
petsch
et
al
b
commerci
avail
proteas
kit
form
bdti
c
demask
via
method
develop
hyglo
acquir
use
cation
buffer
mgso
tri
buffer
method
come
caveat
caveat
associ
use
proteas
proteinas
k
petsch
use
describ
often
come
endotoxin
bound
cation
protein
purifi
petsch
et
al
studi
admit
subtract
small
amount
endotoxin
proteinas
k
inher
materi
receiv
chromatographi
use
serial
fashion
remov
impur
polish
protein
free
minut
amount
impur
contamin
includ
endotoxin
howev
expert
field
awar
difficulti
remov
endotoxin
cation
protein
may
less
wide
known
mask
effect
protein
limulusbas
detect
method
given
assumpt
endotoxin
may
find
obviou
express
system
e
coli
subtl
bioburden
residu
ingress
process
question
aris
mechan
ingress
remain
hidden
three
potenti
avenu
explor
includ
protein
bound
ii
low
endotoxin
recoveri
ler
surfact
mask
iii
endotoxin
iirmi
alreadi
discuss
chap
tenac
endotoxinprotein
bind
recogn
half
heartedli
embrac
analyt
mani
year
histor
procliv
vaccin
contamin
endotoxin
well
document
similarli
schwarz
et
al
found
mani
modern
recombin
protein
reagent
therapeut
drug
routin
contain
endotoxin
level
time
certifi
level
also
describ
chap
petsch
et
al
studi
perform
year
ago
perhap
best
demonstr
complex
relationship
protein
endotoxin
show
larg
amount
endotoxinprotein
bind
mgml
ph
condit
may
consid
much
less
concentr
thu
less
strenuou
mani
current
drug
manufactur
process
inde
mani
biolog
drug
product
concentr
greater
mgml
mgml
common
greater
protein
concentr
come
greater
potenti
endotoxin
bind
capac
ph
import
determin
protein
charg
relat
activ
rel
isoelectr
point
pi
pi
ph
charg
protein
neutral
nonbind
solut
petsch
et
al
studi
find
summar
tabl
human
igg
antibodi
basic
scaffold
upon
mab
base
bind
natur
endotoxin
e
coli
filtrat
limulusbas
test
result
given
endotoxin
releas
via
proteas
exclus
bound
endotoxin
import
blood
stream
full
variou
proteas
rang
specif
also
point
endotoxin
loss
cation
protein
achiev
without
hold
time
period
ii
use
nonpurifi
endotoxin
spike
iii
rel
minim
protein
concentr
mgml
compar
mani
modern
protein
solut
manufactur
today
ler
hold
time
spike
studi
perform
number
day
therefor
without
treatment
one
safe
assum
cation
protein
go
recov
endotoxin
via
limulusbas
test
without
kind
pretreat
anspach
summar
situat
remov
endotoxin
protein
solut
via
affin
sorbent
given
extrem
low
endotoxin
concentr
presenc
substanc
order
magnitud
higher
concentr
owe
high
toxic
endotoxin
still
purif
may
necessari
sever
consequ
deriv
circumst
socal
neg
chromatograph
mode
prefer
allow
bind
byproduct
pollutanther
endotoxinswherea
product
pass
adsorb
without
consider
retent
elut
endotoxin
object
therefor
irrevers
adsorpt
option
may
often
welcom
deduc
fact
adsorpt
equilibrium
process
due
low
endotoxin
threshold
level
tabl
endotoxinprotein
mask
subsequ
proteinas
k
demask
result
lal
test
comparison
four
cation
protein
top
versu
two
anion
protein
bottom
note
higg
molecular
scaffold
mab
show
high
bind
polysorb
citrat
solut
anion
protein
bsa
mous
present
difficulti
detect
ad
endotoxin
lal
larg
amount
endotoxin
eu
bound
protein
endotoxin
ad
natur
endotoxin
filtrat
highli
purifi
standard
expect
requir
low
appar
dissoci
constant
k
endotoxin
sorbent
condit
also
follow
owe
unavoid
interact
substanc
protein
much
higher
concentr
lead
competit
endotoxin
latter
lead
unfortun
situat
endotoxin
often
carri
piggyback
adsorb
extent
depend
differ
strength
interact
mani
compon
involv
evid
protein
difficult
purifi
other
neutral
ph
cation
posit
charg
stick
strongli
neg
charg
endotoxin
bind
abund
protein
may
mask
presenc
endotoxin
view
via
limulusbas
test
look
human
igg
basic
scaffold
mab
difficulti
remov
seen
even
proteas
proteinas
k
digest
drastic
treatment
use
except
destroy
protein
endotoxin
bound
endotoxin
remain
hidden
petsch
et
al
chromatograph
remov
method
today
power
user
awar
simpl
straightforward
limulusbas
test
verifi
remov
endotoxin
cation
protein
without
orthogon
verif
remov
petsch
et
al
show
import
send
sampl
lab
label
gener
eg
process
run
sampl
instead
provid
need
context
help
test
lab
understand
may
test
sampl
contain
cation
protein
fig
need
process
develop
done
post
process
develop
process
valid
process
use
repeatedli
manufactur
develop
place
high
prioriti
commun
endotoxin
content
determin
truli
realiz
without
check
endotoxin
avail
matrix
protein
sampl
true
protein
bind
ler
phenomenon
fig
mab
ph
charg
neutral
pi
shown
ph
pi
protein
carri
net
posit
charg
pi
carri
net
neg
charg
three
main
theori
come
explain
caus
biotherapeut
immunogen
chapter
discuss
expert
opinion
surpris
natur
immun
respons
biolog
therapi
despit
gener
trend
toward
human
drug
remain
immunogen
clinic
set
baffl
drug
develop
principl
human
fulli
human
monoclon
antibodi
self
immunoglobulin
toler
three
current
prevail
paradigm
character
mimeticbas
physic
paramet
associ
product
includ
protein
aggreg
visibl
subvis
particul
molecul
heterogen
glycosyl
pegyl
etc
paradigm
alreadi
becom
deepli
ingrain
biolog
manufactur
oper
ii
iirmibas
impuritycontaminantcentr
view
discuss
chap
sister
mimet
view
base
adjuvant
iii
epitopebas
includ
human
effort
preclud
pathogen
mimick
epitop
structur
therapeut
drug
molecul
develop
manufactur
includ
qc
personnel
appreci
variou
effort
continu
go
reduc
immunogen
biolog
section
seek
highlight
role
manufactur
play
preclus
artifact
microbi
mimet
may
contribut
immunogen
downstream
vantag
littl
widespread
share
knowledg
effort
upstream
molecul
develop
effort
exhaust
attempt
first
human
molecul
recent
improv
predict
preclus
amino
acid
sequenc
could
mistaken
immun
system
pathogen
like
epitop
mimet
iirmi
base
upon
adjuv
view
consid
adjuv
use
histor
pamp
like
lp
rather
still
particul
surfact
emuls
use
empir
decad
even
knowledg
mechan
immun
activ
known
aluminum
salt
alum
squalen
surfact
oil
water
still
use
variou
combin
provok
immun
respons
variou
protein
subvis
particl
stori
chap
demonstr
slow
uptak
adjuvantbas
view
pharma
set
chap
cherney
summar
immunolog
concern
subvis
particl
present
includ
aggreg
protein
feb
pharma
qualiti
newslett
explain
svp
type
amount
protein
aggreg
may
induc
immun
respons
product
clear
cherney
provid
recommend
firm
assess
reduc
risk
face
uncertainti
think
one
svp
subvis
particl
thing
affirm
document
exactli
certain
uncertain
product
one
way
risk
assess
today
hindsight
recent
histori
certainti
surround
import
mimet
control
biolog
process
control
protein
product
aggreg
emuls
surfact
interfac
interact
protein
even
silicon
vial
stopper
well
protein
molecul
heterogen
ie
glycosyl
also
affect
aggreg
iirmi
addit
establish
mimet
adjuv
view
alreadi
thoroughli
discuss
chap
remain
much
less
well
dissemin
industri
perspect
antigen
process
cell
apc
specif
way
process
protein
includ
therapeut
protein
phagocyt
larg
structur
larg
protein
bacteri
cell
viru
particl
etc
degrad
short
constitu
peptid
move
peptid
surfac
display
mhc
ii
molecul
access
tcell
human
protein
mhc
consist
highli
variabl
human
leukocyt
antigen
hla
thu
mhc
present
sampl
immun
milieu
right
size
format
tcr
short
peptid
amino
acid
long
tcr
seem
odd
short
peptid
could
commun
friend
foe
protein
everi
cell
human
pathogen
made
long
strand
amino
acid
break
short
random
piec
seem
intuit
nonproduct
yet
method
recogn
self
foreign
cell
receptor
match
mhc
molecul
confirm
addit
signal
see
fig
see
cousen
mois
degroot
gener
figur
phagocytosi
therapeut
protein
end
present
epitop
cell
idea
small
pathogen
amino
acid
sequenc
size
may
serv
univers
epitop
explor
effort
understand
simplist
complex
topic
biolog
molecul
develop
exampl
immunogen
epitop
sequenc
pathogen
repres
tetanu
toxin
ttd
protein
mani
year
believ
contain
specif
univers
epitop
human
mch
ii
cell
tetanu
toxin
clostridium
tetani
devast
diseas
born
sporeform
anaerob
bacteria
inhabit
soil
water
may
contamin
wound
anaerob
environ
punctur
nail
prolifer
releas
toxin
even
though
vaccin
tetanu
exist
decad
still
kill
peopl
worldwid
paper
list
ttd
univers
epitop
ttd
ttd
specif
epitop
refer
repeatedli
use
histor
vaccin
research
jame
et
al
disput
idea
univers
epitop
due
presenc
mani
differ
mhc
allel
human
genom
accord
sewel
huge
divers
thought
import
ensur
survivor
emerg
infecti
epidem
make
clone
variou
peptid
produc
tetanu
toxoid
sequenc
found
follow
match
tt
mhc
ttderiv
antigen
peptid
present
allel
studi
howev
except
exampl
bold
ad
present
three
allel
four
allel
six
allel
peptid
residu
length
possibl
may
contain
multipl
epitop
other
contain
singl
epitop
truli
promiscu
result
contrast
perceiv
notion
tetanu
toxoid
respons
domin
univers
tcell
epitop
rather
result
illustr
heterogen
tcell
respons
differ
class
ii
allel
individualspecif
variat
tcell
repertoir
jame
et
al
word
rather
univers
epitop
highli
depend
upon
individu
allel
makeup
even
small
sampl
show
match
paper
list
ttd
larg
agreement
first
paper
list
sequenc
howev
although
recent
studi
use
uptod
method
support
histor
defin
univers
antigen
sequenc
refut
one
import
one
see
fig
interestingli
nearli
previous
describ
epitop
contain
within
predict
set
thu
valid
independ
set
result
previou
studi
convers
signific
respons
detect
univers
tt
epitop
correspond
residu
jame
et
al
studi
design
sequenc
overlap
orang
repres
immunogen
sequenc
sequenc
univers
allel
correspond
seem
surpris
studi
differ
immunogen
univers
antigen
structur
deriv
notori
human
pathogen
toxin
variou
sequenc
subset
peptid
ttd
shown
use
vaccin
particularli
polysaccharid
deriv
molecul
call
conjug
vaccin
attach
immunogen
peptid
ie
tetanu
diphtheria
toxin
epitop
polysaccharid
thu
gener
immun
respons
moieti
weber
et
al
provid
immunogen
scale
base
expect
random
sequenc
random
sequenc
amino
acid
mer
polym
assign
score
zero
scale
shown
fig
list
two
immunogen
tetanu
toxin
sequenc
score
around
respect
influenza
ha
hemagglutinin
sequenc
also
score
around
anyth
higher
immunogen
immunogen
ttd
sequenc
use
employ
fig
overlap
sequenc
epitop
determin
immunogen
orang
red
immunogen
green
tetanu
toxoid
ttd
amino
acid
sequenc
short
peptid
epitop
sequenc
larg
overlap
sequenc
found
immunogen
histor
subset
found
immunogen
recent
studi
short
overview
may
exemplifi
difficulti
definit
assign
epitop
immunogen
sinc
claim
caus
immunogen
three
paradigm
epitopebas
mimeticbas
iirmibas
view
chap
might
interest
manufactur
perspect
see
relationship
view
fig
adjuv
view
mimet
iirmi
combin
singl
paramet
isoelectr
point
pi
protein
petsch
et
al
use
pi
major
divid
line
therapeut
protein
basic
neutral
acid
could
seen
correl
difficulti
impur
contamin
remov
process
mimet
iirmi
manufacturingbas
rather
epitopebas
perspect
figur
show
simpl
comparison
immunogen
score
epitopebas
method
rel
protein
isoelectr
point
suggest
may
overlap
two
view
least
protein
given
immunogen
scale
valu
addit
exampl
shown
tabl
accord
scale
eight
four
fig
four
tabl
immunogen
protein
rang
compar
tetanu
toxoid
also
cation
rang
almost
term
isoelectr
point
fifteen
total
molecul
thu
small
specif
compar
novel
protein
sequenc
protein
known
vari
immunogen
potenti
new
protein
therapeut
gdnf
use
treatment
parkinson
diseas
amyotroph
later
sclerosi
al
epimatrix
analysi
howev
score
high
publish
highli
immunogen
peptid
influenza
hemagglutinin
tetanu
toxin
might
caus
observ
side
effect
clinic
use
therapeut
weber
et
al
right
side
graphic
turn
vertic
aid
readabl
group
molecul
immunogen
molecul
also
posit
charg
cation
molecul
pi
refer
pi
cite
follow
hinterferon
campath
mab
thrombopoietin
mous
predict
halbumin
hamylas
saliva
isoform
nativ
fc
homodim
hinsulin
immunogen
scale
weber
et
al
suggest
protein
human
origin
produc
human
recombin
molecul
much
show
antibodi
sequenc
rank
compar
standard
control
epimatrix
protein
immunogen
score
higher
consid
potenti
immunogen
note
lowscor
protein
lower
left
side
scale
known
engend
littl
immunogen
higher
score
protein
upper
left
side
scale
known
immunogen
monoclon
antibodi
adjust
antibodi
score
presenc
predefin
regulatori
cell
epitop
evid
presenc
epitop
decreas
overal
immunogen
antibodi
clinic
discov
peptid
sequenc
identifi
put
cell
epitop
may
potenti
import
aspect
protein
therapeut
develop
weber
et
al
right
ad
isoelectr
point
molecular
weight
da
molecul
list
weber
et
al
left
immunogen
tetanu
toxin
influenza
virusderiv
sequenc
simpl
comparison
shown
drug
pi
immunogen
ignor
mani
complex
factor
theoriz
exacerb
immunogen
true
broad
correl
would
surpris
given
mani
power
purif
techniqu
exist
overcom
impur
howev
manufactur
process
purif
method
differ
abil
remov
impur
compani
compani
process
process
molecul
molecul
indic
molecul
contain
impur
test
methodolog
hail
et
al
use
chap
product
test
subject
fda
studi
impur
lp
hcp
present
level
satisfi
legal
limit
weber
et
al
expert
immunologist
maintain
protein
shown
immunogen
fig
tabl
immunogen
present
sequenc
resembl
short
amino
acid
antigen
epitop
multipl
short
sequenc
resembl
found
pathogen
strongli
bind
mhc
protein
thu
increas
effect
present
cell
receptor
becom
predomin
way
view
case
improv
biolog
vaccin
protein
therapeut
keep
discuss
chap
weber
et
al
describ
need
costimulatori
activ
cell
via
pamp
regardless
epitop
sequenc
regardless
statu
univers
antigen
control
factor
appear
context
cell
epitop
recogn
cell
signal
evok
releas
inflammatori
cytokin
result
express
costimulatori
factor
antigenpres
cell
effector
immun
respons
trigger
absenc
signal
presenc
other
abund
regulatori
cytokin
cell
may
deviat
toward
regulatori
tolerogen
respons
thu
protein
biolog
cell
epitop
may
friend
regulatori
foe
effector
depend
context
respons
weber
et
al
tcr
wildli
divers
type
per
person
per
sewel
difficult
conceiv
obviou
univers
mechan
might
transmit
knowledg
present
epitop
previou
infect
gener
within
tcr
cdr
loop
absenc
prior
knowledg
epitop
might
encount
cell
immun
must
provid
immun
cover
possibl
foreign
peptid
contain
appropri
anchor
bind
self
mhc
molecul
sewel
agre
assert
chap
take
least
two
separ
set
activ
creat
immunogen
protein
desir
vaccin
problemat
biolog
name
clonal
receptor
recognit
antigen
bcrtcr
ii
nonclon
receptor
recognit
pamp
second
costimulatori
signal
direct
licens
nonpamp
receptor
thu
relationship
two
paradigm
epitop
adjuvantbas
could
view
product
mammalian
immun
system
innateadapt
immun
respons
dichotomi
name
necess
signal
respect
signal
given
lymphocyt
receptor
bcrtcr
signal
costimulatori
signal
interestingli
also
describ
combin
upstream
molecul
develop
downstream
manufacturingqc
immunogen
preclus
effort
epitop
versu
adjuv
includ
iirmi
mimet
see
fig
accord
recent
literatur
epitop
pathogen
appar
alway
recogn
highli
specif
way
sewel
say
abandon
oneclonotypeonespecif
paradigm
suggest
clonal
select
theori
favour
oneclonotypemillionsofspecif
realiti
exist
extens
cell
cross
reactiv
mean
heterolog
immun
extend
beyond
crossrecognit
pathogen
high
sequenc
similar
allow
exampl
bcginduc
cell
also
provid
immun
poxvirus
similarli
cell
specif
human
papillomaviru
ymldlqpet
peptid
also
recogn
tmldiqp
peptid
coronaviru
inde
cell
mediat
heterolog
immun
extend
dissimilar
antigen
exampl
cell
specif
immunodomin
gilgfvftl
peptid
influenza
viru
often
recogn
epsteinbarr
viru
epitop
glctlvaml
immunodomin
hivderiv
slyntvatl
antigen
restrict
sewel
sewel
say
later
three
pathogen
epitop
seem
similar
shown
fig
exampl
besid
therapeut
protein
dispar
peptid
epitop
mimick
mhctcr
bind
potenti
contribut
autoimmun
diseas
molecular
mimicri
defin
similar
structur
share
molecul
encod
dissimilar
gene
molecular
mimicri
hypothesi
postul
cell
specif
microbi
mimick
epitop
crossreact
mhc
restrict
selfpeptid
initi
trigger
expans
cell
viral
bacteri
peptid
mhc
complex
cell
crossreact
selfepitop
peripheri
potenti
trigger
autoimmun
respons
latter
case
viral
protein
share
sequenc
homolog
human
protein
rather
share
conform
structur
similar
interest
question
rais
regard
recombin
vaccin
essenti
revers
biolog
question
fundament
reason
vaccin
subunit
protein
viral
microbi
protein
would
less
immunogen
recombin
protein
human
sourc
subunit
vaccin
often
brought
need
immunogen
desir
modern
vaccin
high
puriti
vaccin
make
advers
event
less
like
also
make
vaccin
less
immunogen
therefor
potenti
less
effect
therefor
seem
contradict
aris
human
drug
protein
molecul
immunogen
mani
viral
microbi
recombin
protein
vaccin
drug
like
epitop
like
pathogen
pathogen
immunogen
potenti
vaccin
administ
drug
would
meaning
measur
sinc
everi
modern
subunit
recombin
vaccin
associ
adjuv
thu
inher
immunogen
els
would
nt
vaccin
howev
interest
view
pi
variou
underli
vaccin
protein
produc
without
adjuv
microbi
viral
protein
see
curios
fall
compar
human
protein
note
relev
pi
microbi
viral
protein
versu
eukaryot
protein
purifi
constitu
vaccin
given
michen
graul
determin
pi
anim
virus
within
rang
exclud
encephalomyocard
polio
viru
vaccin
precursor
describ
thomassen
et
al
made
complet
intact
poliovirus
pi
though
polio
vaccin
subunit
vaccin
inactiv
per
baldo
share
similar
pi
rang
describ
mehlin
et
al
express
protein
plasmodium
falciparum
malaria
parasit
eukaryot
protist
e
coli
express
system
mean
pi
trend
toward
insolubl
increas
pi
strike
target
pi
one
solubl
low
pi
valu
appear
tendenc
toward
lack
express
compens
greater
level
solubl
among
express
mean
pi
target
includ
tag
kiraga
et
al
state
schwartz
et
al
knight
et
al
found
membran
protein
larger
basic
nonmembran
one
sinc
modern
human
therapeut
cellsurfacesign
protein
membran
protein
expect
higher
pi
shown
deriv
schwartz
et
al
figur
fig
fig
speak
low
immunogen
characterist
mani
subunit
recombin
vaccin
protein
base
manufactur
consider
rather
epitop
sequenc
therapeut
human
nonvaccin
protein
develop
cssm
therefor
membran
protein
shown
red
pi
pi
viral
mani
microbi
protein
purpl
blue
lower
pi
thu
contrast
mani
human
protein
larger
mw
basic
pi
purifi
express
recombin
subunit
vaccin
protein
stand
stark
contrast
histor
highli
immunogen
vaccin
made
whole
kill
attenu
ie
formaldehyd
see
chap
organ
clarifi
christensen
histor
vaccin
base
live
attenu
kill
bacteria
virus
ie
smallpox
measl
polio
tuberculosi
vaccin
case
proven
effect
recogn
erad
smallpox
reduct
polio
case
case
wild
polio
viru
global
although
effect
vaccin
often
come
risk
side
effect
fever
rash
swell
case
even
vaccin
deriv
infect
latter
case
onethird
polio
case
worldwid
furthermor
largescal
product
ensur
consist
vaccin
challeng
demonstr
number
case
global
shortag
vaccin
one
exampl
declin
global
avail
bcg
vaccin
tuberculosi
million
dose
requir
meet
global
demand
million
dose
made
avail
manufactur
evad
issu
novel
vaccin
strategi
evolv
protect
part
microb
includ
ie
socal
subunit
vaccin
produc
recombin
form
yeast
bacteria
yield
product
high
quantiti
collect
purifi
current
regist
hepat
b
vaccin
base
hepat
b
surfac
antigen
hbsag
produc
yeast
cell
high
puriti
make
vaccineinduc
advers
event
less
like
also
caus
vaccin
becom
much
less
immunogen
thu
less
effect
therefor
grow
need
ad
immunepotenti
also
known
vaccin
adjuv
vaccin
increas
immunogen
christensen
wherea
upstream
develop
molecul
onetim
per
molecul
endeavor
albeit
long
complex
one
downstream
manufactur
product
purif
activ
depend
upon
develop
subsequ
repeat
perform
activ
lot
lot
therefor
upstream
develop
scientist
charg
creat
molecul
less
prone
immunogen
downstream
scientist
charg
ensur
process
thoroughli
remov
impur
ii
pamp
signatur
certain
detect
iii
make
overt
covert
ingress
product
latter
young
scienc
immunolog
perspect
given
recent
iirmi
discuss
tendenc
think
human
epitop
sequenc
makeup
singular
paradigm
govern
immunogen
preclus
effort
may
serv
crowd
adjuvantbas
viewpoint
thu
limit
potenti
manufactur
develop
perform
advanc
care
taken
tri
draw
mani
conclus
overli
complex
phenomenon
ask
question
base
upon
interest
observ
surround
current
complex
theori
protein
therapeut
manufactur
immunogen
occurr
improv
mani
molecul
persist
stubbornli
other
even
fulli
human
protein
epitopebas
view
quickli
becom
deepli
entrench
success
extend
broadli
use
toxoid
epitop
conjug
vaccin
ultramodern
use
cancer
neo
antigen
epitop
cell
therapi
iirmibas
view
recent
emerg
fit
well
wellentrench
mimet
view
share
adjuvantbas
vantag
discuss
import
isoelectr
point
process
develop
subsequ
lab
verif
endotoxin
remov
studi
like
well
potenti
impur
contamin
type
continu
section
assumpt
mask
may
occur
follow
kind
demask
verif
expect
demonstr
endotoxin
remov
process
develop
especi
cation
biolog
protein
isoelectr
point
mab
differ
substanti
despit
common
igg
molecular
scaffold
figur
goyon
et
al
demonstr
rang
isoelectr
pi
valu
howev
ad
remov
endotoxin
often
employ
protein
first
step
depend
upon
pi
affin
protein
mab
occur
via
attach
ig
fc
domain
goyon
et
al
discuss
method
use
determin
pi
import
pi
valu
monoclon
antibodi
purif
cief
high
resolut
techniqu
separ
speci
base
pi
net
charg
take
account
solventexpos
residu
intern
amino
acid
becom
analyt
platform
choic
character
protein
charg
heterogen
determin
experiment
pi
part
aim
evalu
pi
fda
ema
approv
mab
well
dalotuzumab
nist
mab
compar
experiment
result
theoret
calcul
shown
fig
fig
pi
measur
icief
compris
coeffici
variat
cv
three
replic
lower
mab
confirm
robust
icief
alreadi
demonstr
interlaboratori
studi
typic
pi
valu
compris
obtain
mab
except
infliximab
elotuzumab
pi
higher
mab
pi
lower
featur
relat
higher
amount
acid
amino
acid
aspart
acid
glutam
acid
primari
sequenc
therefor
find
confirm
mab
less
basic
mab
agreement
literatur
ionic
properti
mab
crucial
paramet
purif
process
includ
least
one
ion
exchang
step
antibodi
pi
anion
exchang
chromatographi
aex
use
flowthrough
mode
remov
processrel
impur
cex
subsequ
use
remov
charg
processrel
impur
mab
pi
context
cation
mab
pi
especi
pi
may
select
develop
studi
avoid
specif
purif
process
eg
host
cell
protein
remov
viral
inactiv
step
therefor
two
pi
threshold
limit
set
fig
except
reslizumab
pi
panitumumab
pi
eculizumab
pi
mab
pi
higher
therefor
view
fig
see
almost
mab
ph
horizont
green
line
show
least
small
net
posit
charg
furthermor
mab
ph
shown
posit
charg
posit
charg
bind
neg
charg
endotoxin
sometim
good
gener
theori
predict
solubl
protein
minim
near
pi
shaw
et
al
mani
protein
precipit
ph
equal
pi
reason
ph
natur
blood
protein
avoid
spot
mab
shown
closest
interestingli
theoriz
piph
phenomenon
play
role
diseas
malform
protein
accumul
abnorm
proteoform
blood
includ
alzheim
diseas
ad
amyotroph
later
sclerosi
prion
diseas
creutzfeldtacob
diseas
parkinson
diseas
pd
amyloidosi
wide
rang
disord
relationship
pi
protein
bind
affect
perform
endotoxin
remov
studi
studi
use
demonstr
remov
endotoxin
forward
process
gener
establish
log
reduct
valu
lrv
specif
unit
process
limulusbas
test
appli
sampl
receiv
manufactur
intend
show
endotoxin
reduct
variou
process
studi
variou
step
pi
ph
process
solut
taken
account
determin
protein
bind
like
affect
studi
figur
show
simplist
assumpt
pi
ph
relev
studi
thu
studi
may
start
bound
endotoxin
make
remov
look
better
b
solut
prescreen
bound
endotoxin
forward
process
appropri
method
b
provid
great
confid
result
cation
protein
use
reus
resin
impuritycontamin
remov
show
deterior
time
thu
may
add
concern
regard
consist
endotoxin
remov
chromatographi
resin
membran
typic
reus
multipl
time
product
scale
downstream
purif
biolog
key
consider
necessit
repeat
use
high
cost
chromatographi
media
especi
import
consider
protein
chromatographi
becom
workhors
monoclon
antibodi
fc
fusion
protein
purif
process
critic
aspect
ensur
chromatographi
resin
continu
deliv
product
meet
predetermin
qualiti
safeti
attribut
lifetim
resin
sever
mechan
contribut
decay
use
lifetim
chromatographi
resin
repeat
use
impur
andor
residu
product
remain
resin
either
block
pore
andor
block
access
surfac
ligand
addit
consider
protein
resin
leach
degrad
ligand
time
particularli
result
harsh
regener
condit
gener
maximum
number
reus
given
chromatograph
stationari
phase
product
specif
depend
varieti
factor
includ
resin
use
placement
process
level
natur
impur
fig
epistemolog
import
clean
solut
prior
endotoxin
remov
studi
origin
solut
contain
bound
mask
endotoxin
remov
ad
load
spike
appropri
demonstr
remov
endotoxin
fact
endotoxin
bound
mask
prior
reduct
studi
like
make
remov
ad
endotoxin
easier
exist
endotoxin
occupi
presatur
bind
spot
hidden
endotoxin
shown
occur
petsch
et
al
done
studi
proceed
per
b
know
free
potenti
mask
endotoxin
resin
come
contact
product
natur
strip
regener
column
storag
solut
use
resin
expens
come
builtin
assumpt
regard
recommend
depyrogen
procedur
bouletaudet
bernadett
byrn
sergei
g
kazarian
cleaninginplac
cip
protocol
typic
includ
wash
resin
alkalin
solut
prevent
contamin
buildup
sodium
hydroxid
solut
effici
remov
precipit
protein
lipid
nucleic
acid
inactiv
bacteria
virus
yeast
endotoxin
high
ph
condit
cip
also
inactiv
microb
remov
contamin
could
carri
subsequ
purif
cycl
howev
even
cip
mab
bind
capac
protein
resin
bind
capac
decay
purif
run
typic
requir
replac
cycl
replac
singl
industri
scale
protein
column
cost
includ
incur
product
interrupt
import
cost
save
could
result
optimis
cip
protocol
extend
resin
lifespan
protect
resin
microbi
growth
tension
inher
regener
column
resin
remov
opportun
microbi
growth
use
higher
concentr
naoh
protein
column
clean
desir
sinc
improv
efficaci
column
sanit
prevent
microbi
growth
column
storag
yet
high
concentr
damag
column
sinc
regener
condit
predominantli
respons
declin
capac
effort
made
screen
identifi
addit
solut
would
protect
ligand
still
allow
effect
resin
clean
sanit
larg
amount
microorgan
yeast
bacteria
destroy
function
chromatographi
column
media
organ
also
indirect
effect
clog
filter
system
compon
well
produc
harm
substanc
endotoxin
enterotoxin
proteas
tabl
shown
show
sodium
hydroxid
effect
inactiv
number
yeast
bacteria
inactiv
depend
concentr
contact
time
temperatur
clear
tabl
bacteri
spore
might
total
inactiv
sodium
hydroxid
tabl
mention
shown
show
bacteri
endotoxin
reduct
endotoxin
easili
inactiv
bacteria
even
bacteri
spore
kind
studi
highli
empir
thu
need
demonstr
specif
setup
mechan
alkalin
hydrolysi
believ
result
saponif
fatti
acid
old
classic
studi
niwa
et
al
show
hydrolysi
base
naoh
without
heat
reduc
e
coli
lp
pyrogen
moder
without
applic
heat
altern
addit
alcohol
alkalin
degrad
endotoxin
ordinarili
carri
aqueou
solut
requir
sever
hour
rather
high
temperatur
strong
alkali
obtain
appreci
detoxif
decreas
fatti
acid
ester
content
exampl
treatment
n
naoh
hr
result
signific
detoxif
wherea
n
alkali
hr
insuffici
effect
complet
treatment
sodium
hydroxid
longer
interv
affect
antibodyneutr
erythrocytemodifi
capac
result
mark
loss
toxic
pyrogen
histor
heat
view
necessari
accomplic
alkyl
depyrogen
efficaci
also
point
naoh
treatment
seemingli
effect
rais
question
alkyltr
activ
depyrogen
lp
bring
distinct
endotoxin
inactiv
gaug
limulusbas
test
detoxifi
could
remain
activ
adjuvantlik
perspect
rather
antiqu
studi
referenc
wellregard
endotoxin
pioneer
point
contrast
concept
adjuvant
immun
stimul
pyrogen
today
larg
absent
discuss
erridg
describ
potenti
microbi
impur
ingress
via
reagent
protein
eluat
protein
purif
column
fig
evid
reveal
endotoxin
lipopeptid
contamin
may
preval
commerci
sourc
reagent
appreci
previous
exampl
found
eluat
commonli
use
protein
purif
column
contamin
blp
despit
use
ethanol
preserv
column
fig
shown
figur
moreov
enzym
use
routin
protein
tag
remov
mammalian
recombin
protein
express
system
tev
proteas
prepar
enzym
may
commonli
contamin
lp
lipopeptid
presum
reflect
recombin
origin
fig
concern
regard
examin
recombin
protein
deriv
mammalian
express
system
survey
suggest
mani
mammalian
cell
line
may
harbor
ongo
mycoplasma
contamin
find
suggest
signific
potenti
lp
blp
contamin
may
exist
reagent
use
studi
list
tabl
includ
use
bacteri
express
system
vaccin
research
alway
search
new
adjuv
use
naoh
produc
detoxifi
endotoxin
produc
lowpyrogen
mute
proinflammatori
respons
yet
retain
immun
stimul
abil
adjuvant
cellular
remnant
gnb
like
escherichia
coli
lp
naohinduc
vpg
excel
activ
proinflammatori
cytokin
ino
antiinflammatori
cytokin
dual
activ
stimul
macrophag
cell
result
indic
naohinduc
vpg
show
potenc
safe
econom
effect
inactiv
vaccin
candid
microorgan
grow
resin
column
column
treat
caustic
naoh
subsequ
sever
potenti
concern
may
aris
treatment
truli
depyrogen
resin
pyrogen
adjuv
perspect
remain
bacteri
shell
ghost
lp
pamp
molecul
remain
immun
stimul
contamin
state
altern
lp
detoxifi
naoh
retain
immun
stimul
properti
even
eluat
confirm
depyrogen
via
limulusbas
test
recur
concern
biolog
manufactur
process
aris
recent
deriv
perspect
includ
immunolog
context
pamp
adjuv
costimulatori
signal
simpli
pyrogen
low
endotoxin
recoveri
ler
issu
first
identifi
chen
vinther
upset
bet
test
statu
quo
differ
philosoph
fda
sought
address
lack
abil
recov
spike
endotoxin
undilut
drug
product
serv
dissoci
chelat
mask
endotoxin
abund
polysorb
molecul
specif
formul
type
polysorb
acellular
bacteri
ghost
bg
empti
nonliv
bacteri
cell
envelop
commonli
gener
control
express
clone
lysi
gene
e
bacteriophag
studi
vibrio
parahaemolyticu
ghost
vpg
ibid
chelat
thu
endotoxin
detect
state
state
exist
downstream
unit
process
could
pose
potenti
risk
miss
detect
endotoxin
discuss
protein
bind
phenomenon
petsch
et
al
exist
decad
littl
recognit
phenomenon
may
affect
specif
drug
test
like
made
littl
differ
lvp
smd
typic
modul
immun
reaction
good
place
distinguish
endotoxin
control
detect
control
center
around
mani
element
associ
control
strategi
discuss
chap
wherea
detect
necessari
confirm
control
qc
qualiti
expect
distinct
control
detect
confirm
control
function
seen
fig
schwarz
et
al
present
evid
limulusbas
mask
formul
protein
solut
via
ler
phenomenon
though
prevent
detect
endotoxin
nevertheless
support
express
key
cytokin
mask
endotoxin
present
includ
chemokin
interleukin
furthermor
lp
mask
prevent
activ
immun
cell
surfac
molecul
solut
saw
chap
activ
cell
surfac
molecul
mean
therapeut
molecul
target
modul
diseas
process
upon
stimul
lp
monocyt
upregul
activ
marker
costimulatori
molecul
wherea
express
downregul
costimulatori
molecul
especi
import
activ
cell
investig
whether
stimul
mask
lp
could
also
produc
increas
surfac
activ
marker
monocyt
analys
surfac
express
flow
overal
data
show
mask
lp
potent
induc
immun
respons
primari
human
monocyt
schwarz
et
al
fig
loss
detect
blue
via
mask
black
nt
imperil
endotoxin
control
howev
loss
detect
loss
confirm
control
thu
mask
bring
question
continu
control
sinc
contamin
prevent
forev
control
strategi
rather
requir
specif
perform
detect
within
unit
process
product
repeat
drug
batch
import
coreceptor
particip
costimul
one
strongest
receptor
govern
cell
activ
chap
give
idea
mani
biolog
drug
modul
pathway
activ
confirm
immun
modul
activ
mask
lp
need
pyrogen
activ
via
limulusbas
test
exert
immunestimul
effect
biolog
drug
milieu
may
sever
interact
phenomenon
occur
given
protein
formul
give
good
direct
spike
recoveri
two
phenomenon
includ
protein
bind
ler
howev
littl
discuss
overlap
two
phenomena
sinc
practic
speak
mask
mask
depend
specif
drug
may
multipl
opportun
mask
see
fig
pda
task
forc
form
understand
low
endotoxin
recoveri
ler
phenomenon
well
help
standard
perform
endotoxin
hold
time
studi
ler
lht
endotoxin
lht
requir
fda
demonstr
endotoxin
spike
undilut
product
recov
prior
routin
endproduct
qc
test
summari
expect
studi
follow
point
consid
elabor
pda
technic
report
ler
lht
requir
differ
lot
final
biolog
drug
product
submiss
biolog
licens
applic
bla
spike
use
cse
rse
made
origin
suitabl
contain
undilut
drug
product
liquid
reconstitut
test
method
use
use
final
qc
test
spike
level
relev
specif
target
midpoint
standard
curv
recoveri
purpos
minim
assay
variabl
studi
perform
revers
mode
carri
least
day
lht
mimic
condit
manufactur
term
hold
time
temperatur
hold
potenti
overlap
protein
ler
endotoxin
mask
phenomena
factor
affect
sever
list
recoveri
greater
must
achiev
cours
studi
two
consecut
time
point
definit
ler
occur
fda
state
ler
overcom
compani
must
releasetest
individu
lot
biolog
use
rabbit
pyrogen
test
rpt
interim
basi
vitro
demask
test
develop
bla
postapprov
commit
requir
develop
nonrabbit
vitro
test
overcom
ler
specif
product
lht
technic
challeng
overcom
ler
specif
protein
product
challeng
approach
tailor
specif
product
formul
protein
excipi
although
fda
requir
rabbit
pyrogen
test
interim
solut
ler
mask
solut
longer
term
requir
develop
appropri
test
via
bla
post
approv
commit
rabbit
pyrogen
test
hold
legal
signific
biolog
test
rel
insensit
use
fever
fever
tool
rpt
sensit
test
comparison
limulusbas
test
use
common
sensit
euml
tabl
show
summari
interpret
pda
technic
report
case
studi
note
complex
studi
difficult
briefli
summar
reader
consult
origin
report
item
interest
see
pda
tr
http
wwwpdaorgdocsdefaultsourcewebsitedocumentlibrari
bookstorepdatechnicaldocumentslistpdf
develop
manufactur
drug
substanc
manufactur
process
develop
program
identifi
materi
attribut
eg
raw
materi
start
materi
reagent
solvent
process
aid
intermedi
process
paramet
control
risk
assess
help
identifi
materi
attribut
process
paramet
potenti
effect
drug
substanc
cqa
materi
attribut
process
paramet
found
import
drug
substanc
qualiti
address
control
strategi
qualiti
raw
materi
use
manufactur
process
appropri
intend
use
raw
materi
use
oper
near
end
manufactur
process
greater
potenti
introduc
impur
drug
substanc
raw
materi
use
upstream
therefor
manufactur
evalu
whether
qualiti
materi
tightli
control
similar
materi
use
upstream
cfr
part
section
requir
ingredi
anim
origin
use
product
biolog
ingredi
biolog
product
requir
cell
line
use
product
biolog
requir
ingredi
anim
origin
use
product
biolog
compon
requir
control
qualiti
control
ensur
appropri
manag
test
monitor
test
ident
conform
puriti
strength
qualiti
inprocess
materi
shall
test
id
strength
qualiti
puriti
appropri
approv
reject
qualiti
control
usp
uspnf
gener
chapter
ancillari
materi
cell
gene
tissueengin
product
usp
appli
rna
pdna
endotoxin
remov
ii
situat
involv
special
affin
interact
pure
plasmid
dna
bind
specif
charg
chelat
compound
sizeexclus
chromatographi
sec
ultrafiltr
use
composit
polyacrylamid
column
highli
porou
ii
ultrafiltr
use
protein
present
method
capabl
remov
larg
endotoxin
aggreg
alkanediol
one
mani
agent
use
effect
endotoxin
remov
anionexchang
chromatographi
aec
rapid
separ
wide
select
aec
media
sodium
hydroxid
naoh
sanitis
requir
solvent
cationexchang
chromatographi
cec
thought
effici
anion
exchang
term
endotoxin
remov
ii
polycation
ligand
offer
extrem
strong
attractionbind
endotoxin
iii
pei
hydrophil
polym
superior
biocompat
exhibit
hydrophob
interact
endotoxin
pll
work
well
protein
recoveri
still
usabl
bind
capac
exhaust
immobil
hydrophob
ligand
reversephas
chromatographi
rpc
interact
nonpolar
protein
surfac
van
der
waal
forc
high
endotoxin
remov
